Charlotte, NC (PRWEB) June 21, 2011
Aesthetic Factors, LLC, an emerging company focused on autologous, point-of-care systems in dermatology, plastic surgery and wound care, announced the initiation of a research collaboration with The Wake Forest Institute for Regenerative Medicine (WFIRM).
The collaborative efforts will focus on the use of The Selphyl® System in addressing a number of scientific questions in regenerative medicine.
Selphyl® is an FDA cleared Class IIa medical device (through a license with its affiliate Cascade Medical Enterprises, LLC) for the safe, rapid collection and preparation of Platelet-rich Fibrin Matrix from a small sample of blood.
Anthony Atala, MD, director of WFIRM stated, "It is a pleasure to work with Dr. Batra and his team in exploring the biology and potential applications of Platelet-rich Fibrin Matrix as a stand alone or combination therapy to help patients.”
Sanjay Batra, PhD, President and CEO of Aesthetic Factors noted, "I deeply admire the pioneering work of Dr. Atala and his team. The opportunity to evaluate our technology at WFIRM marks a tremendous moment for our company."
WFIRM, led by Dr. Atala, was first in the world to engineer laboratory-grown organs that were successfully implanted into humans. The interdisciplinary team of physicians and scientists at WFIRM is working to engineer more than 30 different replacement tissues and organs and is on the forefront of regenerative medicine.
For more information about The Selphyl® System, visit http://www.selphyl.com, or call 1 877 SELPHYL (1 877 735-7495.)
Information regarding The Wake Forest Institute for Regenerative Medicine, can be found at: http://www.wakehealth.edu/WFIRM/